Focus: Galt Pharmaceuticals is a diagnostics and specialty pharmaceutical company headquartered in Atlanta focused on musculoskeletal and neurology treatments, primarily through legacy marketed products.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Growing — net +9 jobs in 30d
22 jobs added vs 13 removed. Steady team buildout.
Galt is a financially vulnerable legacy-product company suitable only for near-term commercial or operational roles; long-term career growth is severely constrained by absence of pipeline.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole revenue driver for the company, representing 100% of cash generation despite post-LOE status.
Help build intelligence for Galt Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Galt Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
NDA-originated product facing patent cliff in ~3.5 years with no disclosed revenue, indicating minimal market presence.
Niche buccal antifungal with unclear patent expiration but no disclosed revenue contribution.
Post-LOE ANDA formulation with no disclosed revenue, suggesting minimal market differentiation from Forte variant.
1 discontinued, 1 duplicate formulations not shown
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles